The underreporting of results and possible mechanisms of ‘negative’ drug trials in patients with chronic heart failure
- 31 August 2001
- journal article
- review article
- Published by Elsevier in International Journal of Cardiology
- Vol. 80 (1) , 19-27
- https://doi.org/10.1016/s0167-5273(01)00447-8
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Neurohormonal activation in severe heart failure: Relations to patient death and the effect of treatment with flosequinanAmerican Heart Journal, 2000
- The agonising negative trend in monitoring of clinical trialsThe Lancet, 1999
- Heart failure 99 — the Moxcon storyInternational Journal of Cardiology, 1999
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Comparative Efficacy of a DA2/α2 Agonist and a β-Blocker in Reducing Adrenergic Drive and Cardiac Fibrosis in an Experimental Model of Left Ventricular Dysfunction After Coronary Artery OcclusionJournal of Cardiovascular Pharmacology, 1998
- Selective and nonselective dopamine receptor agonists: An innovative approach to cardiovascular disease treatmentAmerican Heart Journal, 1996
- β-Adrenergic Blockers and Survival in Heart FailureNew England Journal of Medicine, 1996
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996
- The xamoterol experience in the treatment of heart failureThe American Journal of Cardiology, 1993
- Neuroendocrine changes post myocardial infarction: Effects of xamoterolAmerican Heart Journal, 1990